- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Natco Pharma Limited — Updates, 03-06-2026: Press Release
03-06-2026 | 11:15 am
03-06-2026 | 11:15 am
NATCO Pharma and Lupin secured U.S. FDA approval for Eribulin Mesylate Injection, a generic equivalent to Halaven®. This drug targets metastatic breast cancer and liposarcoma, tapping into a U.S. market with estimated annual sales of ~$363 Cr.
No comments yet. Be the first to comment!